Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Kunutsor, Setor K ^a   Apekey, Tanefa A ^b   Khan, Hassan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Alkaline phosphatase; Aminotransferases; Cardiovascular disease; Gamma glutamyltransferase; Meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; ENZYME BLOOD LEVEL; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; ENZYMOLOGY; FEMALE; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RISK; UNITED KINGDOM; YOUNG ADULT;

ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; CARDIOVASCULAR DISEASES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GREAT BRITAIN; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84905841696     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.006     Document Type: Article

References (45)

1. Monami M., Bardini G., Lamanna C., Pala L., Cresci B., Francesconi P., et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008, 57:387-392.
2. Yun K.E., Shin C.Y., Yoon Y.S., Park H.S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009, 205:533-537.
3. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Brit Med J 2004, 328:983.
4. Kim H.C., Kang D.R., Nam C.M., Hur N.W., Shim J.S., Jee S.H., et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke 2005, 36:1642-1647.
5. Wannamethee S.G., Sattar N., Papcosta O., Lennon L., Whincup P.H. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol 2013, 33:1070-1076.
6. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British women's heart and health study and meta-ANALYSIS. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
7. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485. e411.
8. Shimizu Y., Imano H., Ohira T., Kitamura A., Kiyama M., Okada T., et al. Gamma-glutamyltranspeptidase and incident stroke among Japanese men and women the circulatory risk in communities study (CIRCS). Stroke 2010, 41:385-388.
9. Goessling W., Massaro J.M., Vasan R.S., D'Agostino R.B., Ellison R.C., Fox C.S. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135:1935-1944.
10. Ford I., Mooijaart S.P., Lloyd S., Murray H.M., Westendorp R.G., de Craen A.J., et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol 2011, 40:1530-1538.
11. Kim H.C., Oh S.M., Pan W.H., Ueshima H., Chuang S.Y., Fujiyoshi A., et al. Association between alanine aminotransferase and intracerebral hemorrhage in East Asian populations. Neuroepidemiology 2013, 41:131-138.
12. Tonelli M., Curhan G., Pfeffer M., Sacks F., Thadhani R., Melamed M.L., et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009, 120:1784-1792.
13. Shimizu Y., Imano H., Ohira T., Kitamura A., Kiyama M., Okada T., et al. Alkaline phosphatase and risk of stroke among Japanese: the circulatory risk in communities study (CIRCS). J Stroke Cerebrovasc Dis 2012, 22:1046-1055.
14. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
15. Kengne A.P., Czernichow S., Stamatakis E., et al. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British health surveys. JHepatol 2012, 57:1083-1089.
16. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis observational stud epidemiology. JAMA J Am Med Assoc 2000, 283:2008-2012.
17. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
18. Wells G.A., Shea B., O'Connell D., et al. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Chêne G., Thompson S.G. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996, 144:610-621.
20. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992, 135:1301-1309.
21. Orsini N., Bellocco R., Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006, 6:40-57.
22. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
24. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999, 18:2693-2708.
25. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
26. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
27. Clarke R., Peden J.F., Hopewell J.C., Kyriakou T., Goel A., Heath S.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
28. Whitfield J.B. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001, 38:263-355.
29. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
30. Franzini M., Corti A., Martinelli B., Del Corso A., Emdin M., Parenti G.F., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques-biochemical similarities with the circulating enzyme. Atherosclerosis 2009, 202:119-127.
31. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
32. Davey Smith G., Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 2003, 32:1-22.
33. Rahmioglu N., Andrew T., Cherkas L., Surdulescu G., Swaminathan R., Spector T., et al. Epidemiology and genetic epidemiology of the liver function test proteins. PloS One 2009, 4:e4435.
34. van Beek J.H., de Moor M.H., de Geus E.J., Lubke G.H., Vink J.M., Willemsen G., et al. The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet 2013, 43:,329-339.
35. Yuan X., Waterworth D., Perry J.R., Lim N., Song K., Chambers J.C., et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008, 83:520-528.
36. Kamatani Y., Matsuda K., Okada Y., Kubo M., Hosono N., Daigo Y., et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010, 42:210-215.
37. Conen D., Vollenweider P., Rousson V., Marques-Vidal P., Paccaud F., Waeber G., et al. Use of a mendelian randomization approach to assess the causal relation of gamma-glutamyltransferase with blood pressure and serum insulin levels. Am J Epidemiol 2010, 172:1431-1441.
38. Kunutsor S., Apekey T.A., Seddoh D., Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 2014, 43:187-201.
39. Soler E.P., Ruiz V.C. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. Curr Cardiol Rev 2010, 6:138-149.
40. Schindhelm R.K., Dekker J.M., Nijpels G., Bouter L.M., Stehouwer C.D., Heine R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191:391-396.
41. Schooling C.M., Kelvin E.A., Jones H.E. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Ann Epidemiol 2012, 22:789-798.
42. Ioannou G.N. Implications of elevated serum alanine aminotransferase levels: think outside the liver. Gastroenterology 2008, 135:1851-1854.
43. Toborek M., Kaiser S. Endothelial cell functions. Relationship to atherogenesis. Basic Res Cardiol 1999, 94:295-314.
44. Yamada J., Tomiyama H., Yambe M., et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 2006, 189:198-205.
45. Fujii Y., Takeuchi S., Tanaka R., et al. Liver dysfunction in spontaneous intracerebral hemorrhage. Neurosurgery 1994, 35:592-596.